Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Newport's Isoprinosine

Executive Summary

Results from U.S./U.K. study in AIDS-related complex patients with T-helper cell depletion do not support efficacy of the agent and will not be used to seek approval of the drug, Newport reports. The firm is discontinuing the U.S./U.K. study, but says it still may seek approval of the drug for ARC if results from an ongoing Scandanavian or Australian study are more promising. Results from the Scandanavian study are expected in early 1989. The Australian study is a long-term trial in HIV-positive patients without symptoms of immunodeficiency....
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS014651

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel